MDK and cancer: To further validate the IFN-γ-MDK regulatory axis, we treated the HCT116 cancer cell line with different concentrations of IFN-γ and verified that activation of MDK by IFN-γ was dose-dependent at both the mRNA (Figure 3A) and protein (Figure 3B) levels.